الفهرس 
INTRODUCTIONOnly 14 pages are availabe for public view
 |  | from | 148 |  |  |
| | | from | 148 | | |
Abstract
This research was conducted as a descriptive transverse analysis to evaluate the clinical effectiveness of Annexin V levels as an early biomarker in prediction of PVT in cirrhotics with and without HCC. This research was undertaken at in NHTMRI. This study involved 20 chronic hepatitis C patients without HCC, 20 chronic hepatitis C patients with HCC and 10 individuals with no evidence of liver disease, 63.3 % were males and 36.66% were females.
The cirrhotics were recruited for 12 months and were examined at baseline and after 12 months by CBC, liver function tests, PT, plasma AnxV and abdominal Doppler US. At the termination of this work, PVT was found in 16 (17.7 %) cirrhotic patients, 6 cirrhotics from group 1 (cirrhotics without HCC) and 10 cirrhotics from group 2 (cirrhotics with HCC). The cirrhotics who developed PVT were categorized as the group of PVT, while cirrhotics who did not develop PVT were categorized as the group of non-PVT. Twelve- months incidence of PVT was 17.7% in all cirrhotics, being12.7% in cirrhotics with HCC and 22.7% in cirrhotics without HCC. Cirrhotics with HCC displayed higher levels of plasma AnxV than cirrhotics without HCC and healthy individuals. Also, cirrhotics who developed PVT within the recruitment duration displayed higher plasma levels of AnxV than cirrhotics who did not develop PVT.